The predictive value of tumor mutation burden for immune checkpoint inhibitors therapy in non-small cell lung cancer is affected by patients' age

• Główni autorzy: Yongfeng Wu (Autor), Jinming Xu (Autor), Jiawei Xu (Autor), Yiqing Wang (Autor), Luming Wang (Autor), Wang Lv (Autor), Jian Hu (Autor)
• Format: Książka
• Wydane: BMC, 2020-04-01T00:00:00Z.
• Hasła przedmiotowe: article
• Dostęp online: Connect to this object online.

Abstract High tumor mutation burden (TMB), which is associated with increased tumor immunogenicity, has been identified to predict improved response to immune checkpoint inhibitors (ICIs) therapy in non-small cell lung cancer (NSCLC). As host immunity is also significant to eliminate cancer cells, h...